Disease Domain | Count |
---|---|
Nervous System Diseases | 3 |
Infectious Diseases | 3 |
Endocrinology and Metabolic Disease | 2 |
Top 5 Drug Type | Count |
---|---|
Herbal medicine | 5 |
Small molecule drug | 4 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date29 Aug 2019 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date31 May 2019 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date30 May 2019 |
Start Date06 Aug 2024 |
Sponsor / Collaborator |
Start Date07 Apr 2024 |
Sponsor / Collaborator |
Start Date01 Apr 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Fuke Qianjin Capsule | Pelvic Inflammatory Disease More | Approved |
Fuke Qianjin Tablets | Endometritis More | Approved |
Gemfibrozil ( PPARα ) | Hyperlipidemias More | Approved |
Trepibutone | Biliary Tract Diseases More | Approved |
Buxue Yimu Pill | Abdominal Pain More | Approved |